Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 634

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Medical Care Costs Associated with Cancer Survivorship in the United States

Open access
Mariotto, Angela B., Enewold, Lindsey, Zhao, Jingxuan, Zeruto, Christopher A., Yabroff, K. Robin·2020·Cancer Epidemiology, Biomarkers & Prevention

Published version of a preprint

Abstract

Background: The prevalence of cancer survivorship is increasing. In this study, we provide contemporary population–based estimates and projections of the overall and site-specific cancer-attributable medical care costs in the United States. Methods: We identified survivors aged ≥65 years diagnosed with cancer between 2000 and 2012 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database and used 2007 to 2013 claims to estimate costs by cancer site, phases of care, and stage at diagnosis. Annualized average cancer-attributable costs for medical care (Medicare Parts A and B) and oral prescription drugs (Medicare Part D) were estimated by subtracting costs between patients with cancer and matched controls. Costs are reported in 2019 U.S. dollars. We combined phase-specific attributable costs with prevalence projections to estimate national costs from 2015 through 2030. Results: Overall annualized average costs were highest in the end-of-life–cancer death phase, followed by the initial and continuing phases (medical care: $105,500, $41,800, and $5,300 and oral prescription drugs: $4,200, $1,800, $1,100, respectively). There was considerable variation in costs by cancer site and stage. Overall national costs in 2015 were $183 billion and projected to increase 34% to $246 billion by 2030, based only on population growth. Conclusions: Phase of care cancer-attributable cost estimates by cancer site and stage are key inputs for simulation models and cost-effectiveness analyses. Impact: The national cancer-attributed medical care costs in the United States are substantial and projected to increase dramatically by 2030, due to population changes alone, reflecting the rising burden of cancer care among cancer survivors. See the interview with Angela B. Mariotto, PhD, recipient of the 2024 CEBP Frederick P. Li Impact Award: https://vimeo.com/992980417

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-19-1534

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 5

  1. Bradley, 2017, Antineoplastic treatment of advanced-stage non-small-cell lung cancer: treatment, survival, and spending (2000 to 2011), J Clin Oncol, 35, 529, 10.1200/JCO.2016.69.4166 · DOI
  2. Kaye, 2018, Costs of urologic cancer care across the disease continuum, J Urol, 199, E1019, 10.1016/j.juro.2018.02.2573 · doi:10.1016/j.juro.2018.02.2573
  3. Yu, 2005, CANSURV: a Windows program for population-based cancer survival analysis, Comput Methods Programs Biomed, 80, 195, 10.1016/j.cmpb.2005.08.002 · doi:10.1016/j.cmpb.2005.08.002
  4. Chhatwal, 2015, Are high drug prices for hematologic malignancies justified? A critical analysis, Cancer, 121, 3372, 10.1002/cncr.29512 · DOI
  5. Lam, 2018, Spending among patients with cancer in the first 2 years of accountable care organization participation, J Clin Oncol, 36, 2955, 10.1200/JCO.18.00270 · doi:10.1200/jco.18.00270

Cited by

See all 634

Metadata

Authors
Mariotto, A. B., Enewold, L., Zhao, J., Zeruto, C. A., & Yabroff, K. R.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2020-07-01
Volume
29
Issue
7
Pages
1304-1312
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W3033718997
Cited by
634
References
27
FWCI
63.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medical Care Costs Associated with Cancer Survivorship in the United States. https://app.cochat.ai/papers/10.1158/1055-9965.epi-19-1534
The paper
Mariotto, A. B., Enewold, L., Zhao, J., Zeruto, C. A., & Yabroff, K. R. (2020). Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-19-1534

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.